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The cisplatin analogue 1R,2R-diaminocyclohexane(trans-diacetato)(dichloro)platinum
IV (DAP) is a DNA-damaging agent that will be
entering clinical trials for its potent cytotoxic effects against cisplatin-resistant tumour cells. This cytotoxicity may reside in its ability to
selectively activate G1-phase checkpoint response by inhibiting CDKs via the p53/p21 pathway. We have now evaluated the role of
another CDK inhibitor p27 as a contributor to DAP-mediated inhibition of G1-phase CDK2 activity. Our studies in ovarian A2780
tumour cells demonstrate that p27 levels induced by DAP are comparable to or greater than those seen for p21. The induction of
p27 is not through a transcriptional mechanism, but rather is due to a four-fold increase in protein stabilisation through a mechanism
dependent on p21. Moreover, DAP-induced p21 promoted the selective increase of p27 in the CDK2 complex, but not in CDK4
complex, and this selective increase contributed to inhibition of the CDK2 kinase activity. The inhibited complex contained either p27
or p21, but not both, with the relative levels of cyclin E associated with p27 and p21 indicating that about 25% of the inhibition of
CDK2 activity was due to p27 and 75% due to p21. This study provides the first evidence that p27 upregulation is directly attributable
to activation of the p53/p21 pathway by a DNA-damaging agent, and promulgates p53/p21/p27 axis as a significant component of
checkpoint response.
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A major limitation in the therapy of cancer is the onset of
drug resistance. In this regard, the cisplatin analogue 1R,2R-
diaminocyclohexane(trans-diacetato)(dichloro)platinum
IV (DAP)
will undergo clinical trials as a therapeutically promising DNA-
damaging agent owing to its ability to circumvent cisplatin
resistance (Kido et al, 1993; Siddik et al, 1994; Mujoo et al, 2003,
2005), but the precise mechanism of how DAP accomplishes this
remains to be resolved. However, its ability to induce G1-phase cell
cycle arrest may be a significant therapeutic feature, and this is
supported by the recent demonstration that selective small
molecule inhibitors of the G1-phase CDK4/cyclin D or CDK2/
cyclin E complex are cytotoxic (Senderowicz, 2003). Our previous
investigations using A2780 ovarian cancer cell line as a model
system have established that DAP specifically and simultaneously
inhibited activities of these two G1-phase kinases (Kuang et al,
2001; He et al, 2005). To affect inhibition, activation of the p53-p21
pathway was essential, and this resulted in the binding of the
induced p21 to both CDK complexes. Thus, it is likely that these
inhibitory effects of DAP on G1-phase CDKs induce drug-
dependent cytotoxicity and contribute to its ability to circumvent
cisplatin resistance. Indeed, deletion of p21 in colon tumour cells
prevented DAP-mediated cell cycle effects (Kuang et al, 2001; He
et al, 2005), which generally precede cell death. This is also
consistent with our report that inhibiting p53 function leads to
DAP resistance (Hagopian et al, 1999). Moreover, in cisplatin-
resistant tumour cells, p21 is induced by DAP but not cisplatin
(Mujoo et al, 2003, 2005), and this supports the premise that
inhibition of CDKs may be necessary for DAP to circumvent
cisplatin resistance. Therefore, it becomes critically important to
fully understand the mechanism of G1-phase checkpoint response
induced by DAP.
The role of p21 in DAP-induced G1 checkpoint response is in
keeping with numerous reports that have demonstrated p21 to be a
critical mediator of G1-phase cell cycle arrest following exposure
to DNA-damaging agents (Macleod et al, 1995; Waldman et al,
1995). However, p27 upregulation can also occur following DNA
damage with UV radiation or antitumour drugs, including
cisplatin (Petrocelli and Slingerland, 2000; Zhou et al, 2004), and
p27 has the potential to inhibit CDK2/cyclin E and, thereby induce
G1-phase arrest, regulate cell growth and, as a result, influence
outcome of therapy with antitumour agents (Balasubramanian
et al, 1999; Qin and Ng, 2002), which could possibly include DAP.
In contrast, both p21 and p27 also have counterintuitive, but
essential roles in the assembly of the active CDK4 complex (Cheng
et al, 1999). Despite such similarities in functions, it is noteworthy
that underlying mechanisms regulating p21 and p27 induction
are distinct, with regulation occurring predominantly at the
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stranscriptional level for p21 and at the post-translational level for
p27. However, the induction of p27 is poorly understood. On the
other hand, some evidence exists to indicate that degradation of
p27 is mediated via the proteasome pathway, which requires initial
phosphorylation of p27 at Thr-187 for recognition by the E3
ubiquitin ligase SCF/Skp2 complex (Bloom and Pagano, 2003).
Therefore, p27 levels may be induced by mechanisms that inhibit
p27 degradation, such as that observed with proteasome inhibitors
MG132 and lovastatin (Lee and Goldberg, 1998; Rao et al, 1999), or
following downregulation of Skp2 by siRNA (Jiang et al, 2005).
There are scant reports to suggest that p21 may also increase p27
levels (Liu et al, 2000; Steinman et al, 2001; Munoz-Alonso et al,
2005), but other studies contradict this, as no increases in p27 were
demonstrated when p21 was induced either ectopically (Yamamoto
et al, 1999) or following treatment with UCN-01 (Facchinetti et al,
2004).
We have previously observed that p27 is bound to the CDK2
complex in lysates from cells exposed to DAP (He et al, 2005), but
the underlying mechanism or significance of this binding was not
delineated. As checkpoint response to DAP-induced DNA damage
through CDK inhibition may trigger cytotoxic effects, it is
important to know the consequence of the binding of p27 to
CDK on its kinase activity. In the present study, therefore, we have
investigated the effect of DAP on p27 levels, and whether the p27
participates in inhibiting CDK2/cyclin E. Our results indicate that
p27 induction by DAP is substantial and comparable to that seen
for p21. More importantly, we demonstrate for the first time that
DAP as a DNA-damaging agent induces p27 in a p21-dependent
manner, and that p27 contributes significantly in inhibiting CDK2/
cyclin E activity in ovarian A2780 tumour cells.
EXPERIMENTAL PROCEDURES
Chemicals, tissue culture and cytotoxicity assessment
DAP was synthesised as reported previously (Ali Sr. et al, 2000),
and a stock solution was prepared in deionised water. Cyclo-
heximide and MG132 were purchased from Sigma Chemical
Company (St Louis, MO, USA). A2780 cells were maintained as
monolayer cultures in RPMI 1640 medium supplemented with 10%
foetal bovine serum. As described previously (Hagopian et al,
1999; Kuang et al, 2001), the antiproliferative effect, viability or
apoptosis was assessed with a range of DAP concentrations using
the MTT assay after 5 days of drug exposure, trypan blue exclusion
after 4 days of drug exposure or Annexin V assay after 3 days of
drug exposure, respectively. These were optimal times for
assessing these effects. The IC50 (drug concentration inducing
50% cytotoxicity) was assessed from fitting a sigmoidal curve to
the data using the SigmaPlot 2000 software program, and the data
are presented as mean7s.e. (N¼7 separate data sets). For
biochemical and molecular assays, cells (1–1.3 10
6) were plated
in 100mm culture dishes and cultured for at least 24h before the
cultures were changed into fresh medium containing 0.6mM DAP.
The cells were further cultured for indicated times before they were
extracted for total proteins by using procedures described
previously (Kuang et al, 2001).
Plasmids and transfection
His-p21 and His-p27 vectors and human p21 or p27 cDNA were
kindly provided by Dr Mong-Hong Lee. The cDNA was used as the
template for PCR amplification. For the myc-p21 vector, the
forward primer was 50-ccggaattcggatcccgatgtcagaaccggctggg-30,
which contained an EcoRI site, whereas the reverse primer
50-ccgctcgagttagggcttcctcttggagaa-30 contained an XhoI site. For
Myc-p27, the forward primer 50-ccggaattcggatcccgatgtcaaacgtgc
gagtgtc-30 and the reverse primer 50-ccgctcgagttacgtttgacgtcttct
gagg-30 contained identical restriction sites. After the PCR product
was digested with both EcoRI and XhoI enzymes, it was subcloned
into pCMV-Myc vector (Clontech, Mountain View, CA, USA).
Myc-p21, Myc-p27 or empty vector was transfected into A2780
cells with LipofectAMINE 2000 (LF2000, catalogue no. 11668-019)
from Invitrogen (Carlsbad, CA, USA), using the manufacturer’s
instructions (version: 07/09/2004). Cells were exposed to the
transfection mixture containing 4ml of LF2000 and 2mgo f
plasmids for 5h, washed and then replenished with normal media.
Cells were re-incubated and collected after 24h to prepare lysates,
as described before (Kuang et al, 2001).
Northern blot analysis
The procedure has been previously reported by us (He et al, 2005).
Briefly, total RNA was extracted from A2780 cells and then
separated by electrophoresis through a 0.8% agarose gel contain-
ing 1.5% (vv
 1) formaldehyde. RNA was transferred to nylon
membranes, hybridised with
32P-labelled p27 or glyceraldehyde-3-
phosphate dehydrogenase cDNA at 421C for 18h, and washed with
0.1 standard saline citrate/0.1% sodium dodecyl sulphate (SDS)
for at least 30min. Blots were then exposed to X-ray film for 6–16h.
RNA interference
Both p21 siRNA duplexes (catalogue ID 1621), which targets a
proprietary segment in Exon 3 of p21 mRNA, and control siRNA
(catalogue ID 4611) were purchased from Ambion (Austin, TX,
USA). A2780 cells were transfected with 100nM siRNA using
LipofectAMINE 2000 (LF2000), as described above. The depletion
of p21 protein levels by siRNA is maintained for at least 2 days,
and all experiments were completed within this time. Cells were
incubated with the transfection mixture for 5h, washed, re-
incubated with complete media for 1h, and then exposed to DAP
(0.6mM final concentration). Cells were collected at 30h after
initiating DAP treatment, and lysates prepared, as described
above.
Immunoprecipitation, immunoblotting and kinase assay
Immunoprecipitation was performed as described previously
(Kuang et al, 2001). The antibodies used to immunoprecipitate
CDK4 (sc-260), CDK2 (sc-163), cyclin D (sc-718), p21 (sc-397) and
p27 (sc-528) were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). The antibody to immunoprecipitate cyclin
E (PC438) was purchased from Oncogene Research Products
(Boston, MA, USA).
Immunoblotting for individual proteins was performed as
described previously (Kuang et al, 2001). Primary antibodies used
to immunoblot CDK4 (MS-299), CDK2 (MS-617) and p27 (MS-
256) were purchased from Neomarkers Inc. (Fremont, CA, USA).
Those used to immunoblot cyclin D1 (sc-20044), cyclin E (sc-247)
and p21 (sc-6246) were obtained from Santa Cruz Biotechnology,
whereas the antibody for b-actin (A5060) was purchased from
Sigma Chemical Company (St Louis, MO, USA). The horseradish
peroxidase-conjugated secondary antibody was acquired from
Amersham Pharmacia (Piscataway, NJ, USA). The protein bands
on immunoblots were visualised by ECL detection (Amersham
Pharmacia) using different lengths of exposures, with exposures
that gave linear or near-linear range of signals selected. To
quantify signals on immunoblots, the developed films were
scanned and band densities analysed with NIH Image software
(version 1.62).
Simultaneous quantification of p21 and p27 on immunoblots
was validated using calibrated amounts of purified standard
proteins. Recombinant His-tagged p21 and p27 were produced in
E. coli, purified by affinity chromatography on Ni-NTA agarose
column according to the manufacturer’s instruction (Qiagen Inc.,
p21-dependent upregulation of p27 following DNA damage
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sValencia, CA, USA), and quantified using bovine serum albumin
(Sigma) as the standard. Recombinant p21 and p27 proteins of
known molar ratios were then simultaneously separated by SDS–
PAGE, transblotted to nitrocellulose membrane and immuno-
blotted with a combination of p21 and p27 monoclonal antibodies.
For maximal primary antibody bindings, the blots were incubated
with 2mgml
 1 of each of the antibodies at 41C for at least 14h. This
antibody concentration was 5–10 times higher than the concen-
tration used for our standard immunoblots, and the 14-h
incubation time was 4–7 times longer than the standard
procedure. After exposure to the primary antibody binding, the
blots were processed as for the standard immunoblots. Finally, the
simultaneously developed p21 and p27 bands on the same
immunoblot were quantified and their relative intensities deter-
mined. Comparison of the relative protein intensities by immuno-
blot analysis against relative Coomassie blue staining intensities
allowed an assessment of whether it was valid to determine p21
and p27 simultaneously on the same immunoblot.
Kinase assay to assess CDK2 complex activity was performed as
described before (Kuang et al, 2001).
Gel filtration chromatography
All gel filtration chromatographies were performed at 41C on a 40-
ml Ultrogel AcA34 column (LKB, Houston, TX, USA) with a buffer
containing 80mM b-glycerophosphate, 20mM EGTA, 150mM NaCl,
15mM MgCl2 and 1mM diothiothreitol. The molecular weight
standards used to calibrate the column were purchased from Bio-
rad (Hercules, CA, USA) and Amersham (Piscataway, NJ, USA).
For each gel filtration, 0.5ml of the standards or crude cell lysates
supplemented with 0.5mg of purified glutathione S-transferase
were loaded onto the column and chromatographed at a flow rate
of B0.3mlmin
 1 with collection of 1-ml fractions. Immediately
after chromatography, 40ml aliquots were taken from fractions 19
to 35 and separated by 12.5% SDS–PAGE. The membranes were
then immunoblotted with anti-p27 antibody using the standard
procedure. To normalise the signals from different chromatogra-
phies for comparison, the highest signal for each protein from each
chromatography was arbitrarily defined as 100 and other signals
were normalised to this.
Immunoprecipitation for protein identification by mass
spectrometry
Fifteen millilitres of crude cell lysates (B10mgproteinml
 1) were
prepared from untreated or DAP-treated (0.6mM 30h) A2780
cells as described above, and pre-absorbed for 4h at 41C with
200ml of protein-A agarose (Sigma). To isolate the p27-containing
complex, the pre-cleared cell lysates were incubated overnight at
41C with 20mg of polyclonal anti-p27 antibodies or rabbit IgG
(Sigma) that were covalently linked to 30ml of Affi-prep protein A
beads (Bio-Rad) through dimethylpimelimidate catalysed reaction
(Schneider et al, 1982). The beads were then washed six times for
3h each time with 0.5% NP-40, 150mM NaCl, 2mM EDTA, 2mM
EGTA, 5mM sodium b-glycerophosphate, 10mM NaF, 10%
glycerol, 1mM DTT and 1mM PMSF in 50mM Tris-HCl (pH 7.4),
and the precipitated proteins were eluted with SDS–PAGE sample
buffer and resolved by 12.5% SDS–PAGE. Following electro-
phoresis, each gel slab was fixed overnight in 40% ethanol and 10%
acetic acid and washed first for 10min with 40% ethanol and then
for another 15min with deionised water. The gel was next
sensitised by a 1-min incubation in 0.02% sodium thiosulphate
followed by two 1-min rinses with distilled water. After rinsing, the
gel was submerged in 0.1% silver nitrate for 30min and developed
in 0.04% formalin in 3% sodium carbonate to desired intensities.
The development was stopped by addition of one-tenth volume of
2.3 M citric acid to the developer and incubation of the gel in this
solution for 15min. The gel was then rinsed three times for 10min
each time with distilled water and stored in distilled water at 41C
(Morrissey, 1981; Shevchenko et al, 1996).
Protein identification by mass spectrometry
Polypeptide bands of interest were excised from the silver-stained
gels and de-stained with the Invitrogen Silver Quest kit (Carlsbad,
CA, USA). After de-staining, the bands were washed five times with
distilled water and twice with 25mM ammonium bicarbonate in
50% acetonitrile. The bands were then digested for 20h with
trypsin (Promega, Madison, WI, USA) in 25mM ammonium
bicarbonate, and the peptide fragments were extracted twice with
0.01% trifluoroacetic acid in 50% acetonitrile and concentrated to
less than 10ml by centrifugation in a Speedvac (Thermo Savant,
Holbrook, NY, USA). The peptides were purified by HPLC on C-18
Ziptip (Millipore, Bedford, MA, USA) by using 2% acetonitrile/
0.1% formic acid to wash and 70% acetonitrile/0.1% formic acid to
elute the peptides. After the acetonitrile was removed from the
collected samples by centrifugation in a Speedvac for 2–3min,
peptide mass fingerprinting (PMF) was performed on a Voyager
DE-STR MALDI TOF instrument (Applied Biosystems, Framing-
ham, MA, USA) in positive ion and reflected mode. Dried droplet
deposits of a-cyano-4-hydroxycinnamic acid were prepared by
mixing the peptide solutions 1:1 with 10mgml
 1 matrix in
methanol. Database searching was performed by using Mascot
(http://www.matrixscience.com) and Protein Prospector (http://
prospector.ucsf.edu). To validate PMF results, peptides were
sequenced by using an LCQ Deca XP electrospray quadrupole
ion trap mass spectrometer (Thermo Finnigan, San Jose, CA, USA)
coupled to an HP 1090 liquid chromatography (Agilent, Palo Alto,
CA, USA). The solvent system for the HPLC included solution A
(2% acetonitrile/0.01% trifluoroacetic acid) and solution B (98%
acetonitrile/0.01% trifluoroacetic acid). A 40-min linear gradient of
5–60% B was run to elute the peptides from a 0.3-mm C-18
column (Vydac, Hesperia, CA, USA). Data-dependent acquisition
was performed for 60min by using two MS-MS steps after each
MS1. Database search with the MS-MS data was performed with
Sonar (Genomic Solutions, Ann Arbor, MI, USA).
RESULTS
Cellular effects of DAP
The cellular effects of DAP were assessed against A2780 cells using
three different standard assays, namely mitochondrial reduction of
the MTT dye, cellular membrane integrity by trypan blue exclusion
and Annexin V apoptotic assay. Interestingly, the IC50 determined
with each of these assays were similar, with 0.2270.05mM obtained
in the MTT assay, 0.2670.03mM with trypan blue and
0.3170.09mM by Annexin V. Therefore, the 0.6mM drug concen-
tration used predominantly in the following studies was about
2–3 IC50 level. This exposure level has been previously demon-
strated by us to preferentially induce G1-phase arrest in A2780
cells (Kuang et al, 2001).
DAP treatment upregulates the expression of p27
To explore whether p27 plays a role in DAP-induced inhibition of
G1-phase progression, we treated A2780 cells with different
concentrations of DAP (0.2–0.8mM) for 30h and determined
whether this treatment increased expression of p27. Immuno-
blotting of crude cell lysates showed that p21 was induced in a
dose-dependent manner (Figure 1A). p27 was also induced in
parallel, but the induction did not increase further above 0.4mM.
To establish a temporal profile, we treated A2780 cells with 0.6mM
of DAP for up to 36h and determined changes in the levels of p21
and p27. Immunoblotting of crude cell lysate following DAP
treatment showed that p21 was induced at 12h, reaching
p21-dependent upregulation of p27 following DNA damage
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smaximum levels during the next 18–36h time period. Similarly,
p27 was induced at 24h and reached plateau levels by 30h
(Figure 1B). Together, these results demonstrate that DAP
treatment induces both p21 and p27. However, it is apparent that
induction of p27 lags behind that of p21, suggesting the possibility
that p21 may act as a positive regulator of p27.
Although both p21 and p27 levels increase during DAP
treatment, it is difficult to assess the quantitative increase of one
relative to the other. This is inherent to the immunoblot technique
as densitometric quantification is influenced by several factors,
including protein loading, interaction with the antibody, ECL
reaction and time of film development. To accurately quantify
relative levels of each inhibitor in this study, immunoblots were
developed simultaneously with both anti-p21 and anti-p27
monoclonal antibodies under saturating conditions (see Experi-
mental Procedures). Under such conditions, if the monoclonal
antibodies recognise p21 and p27 with similar efficiencies, then
Coomassie blue staining and immunoblot signals of purified
inhibitor proteins should give similar p27:p21 ratios for the band
intensities. The results from duplicate protein loading are
presented in Figure 1C, and demonstrate that the relative levels
of p27 (lanes 1 and 2) and p21 (lanes 3 and 4) are similar with
either Coomassie staining or immunoblot. This validation of the
approach with purified proteins enabled crude lysates from DAP-
treated cells to be immunoblotted for p21 and p27 simultaneously
in an identical manner. The results demonstrate that although the
level of p27 greatly exceeded that of p21 in untreated cells, the
difference became less pronounced (p2-fold) after 24–36h of
DAP treatment (Figure 1D). It is notable that the absolute amount
of p27 induced is similar to or greater than p21, suggesting the
possibility that as with p21, p27 also contributes to DAP-mediated
inhibition of CDK4 and CDK2 activities.
DAP upregulates p27 by inhibiting its degradation
The previous section demonstrated that DAP treatment leads to
elevation in p27 levels. To explain this elevation, we first examined
the effect of DAP on mRNA levels of p27 by Northern blot analysis.
However, there was no change in the message, ruling out a
transcriptional mechanism for p27 upregulation (Figure 2A). To
examine inhibition of p27 degradation as a possible cause, we
incubated control or DAP-treated A2780 cells with the protein
synthesis inhibitor cycloheximide and determined the half-life of
p27 in parallel with p21. Immunoblotting of crude lysates from
cells collected at different time points during cycloheximide
treatment, followed by quantification of bands on immunoblots
and then normalising to b-actin, showed that the half-life of p27
increased from 0.75 to 3h in response to DAP treatment
(Figure 2B). In contrast, the half-life of p21 of about 1.25h was
unaffected by DAP. These results indicate that DAP-induced
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Figure 1 DAP upregulates the expression of p21 and p27. (A) A2780 cells were incubated with different concentrations of DAP for 30h. Crude cell
lysates were prepared and immunoblotted individually with antibody specific to p21, p27 or actin. (B) Total proteins extracted from A2780 cells treated
with DAP (0.6mM) for the indicated lengths of time were immunoblotted individually with antibody that recognises each of the indicated protein. (C)
Purified His-tagged p27 and p21 in about a 2:1 ratio were separated by SDS–PAGE and stained with Coomassie blue (left panel). The same samples were
also diluted 1:1000 and simultaneously immunoblotted with anti-p27 and anti-p21 antibodies under saturating immunoblotting conditions. The Coomassie
blue staining and immunoblot signals were then quantified by densitometry, and the mean levels normalised to the signal for p27 were plotted (right panel).
(D) Total proteins extracted from A2780 cells treated with DAP (0.6mM) for 0, 24 and 36h were simultaneously immunoblotted with anti-p21 and anti-p27
antibodies (left panel). The signals were quantified, normalised against the level of p27 at 0h and plotted (right panel).
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supregulation of p27 is due to increased stability of p27. To
consolidate this finding, we determined the effect of the
proteasome inhibitor MG132 on p27 levels in control and DAP-
treated cells. Immunoblotting of crude cell lysate demonstrated
that MG132 treatment increased p27 levels in control cells, but not
DAP-treated cells. However, MG132 treatment increased p21 levels
in both control and DAP-treated cells (Figure 2C). These results
indicate that DAP upregulates p27 primarily by inhibiting p27
protein degradation.
Upregulation of p27 by DAP is dependent on p21
To examine if upregulation of p27 results from p21 induction, we
first knocked down p21 expression by p21-specific siRNA and
determined the effect on p27 induction in response to DAP
treatment. Immunoblotting of crude lysates from control siRNA
or p21 siRNA-transfected cells showed that siRNA reduced
p21 to undetectable levels, with a concomitant small decrease in
basal p27 levels (Figure 3A). With DAP, the siRNA abrogated
induction of both p21 and p27, whereas it did not prevent
p53 induction. As a complimentary approach, we transfected
A2780 cells with an expression construct for myc-tagged p21
(myc-p21) to determine whether increasing p21 levels in the
absence of DAP treatment is sufficient to upregulate p27.
Immnublotting of crude cell lysate from cells transfected
with control vector or myc-p21 construct demonstrated that the
level of p27 increased by 2- to 3-fold in p21-transfected cells
(Figure 3B). These results indicate that p21 induction is
responsible for upregulating p27 during DAP-induced G1-phase
checkpoint response.
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Figure 2 DAP-induced p21 increases p27 by inhibiting p27 degradation. (A) Total RNA extracted from A2780 cells that had been treated with 0.6mM
DAP for the indicated length of time was hybridised with
32P-labelled p27 and GAPDH cDNAs. (B) Control or 30-h DAP-treated A2780 cells were
incubated with PBS or 4mM cyclohexmide for 8h. Cells were collected at the indicated time points (the 30-h time point after 0.6mM DAP treatment was
arbitrarily set as time zero). Crude cell lysates were then separated with SDS–PAGE and immunoblotted with antibodies specific for p21, p27 and actin,
respectively (left panel). The bands were quantified by densitometry, normalised to actin band intensity and plotted against time, with signal at time zero set
at 100% (right panel). (C) Control or DAP-treated (0.6mM; 30h) A2780 cells were incubated with vehicle or 10mM MG132 for 6h. Crude cell lysates were
then separated with SDS–PAGE and immunoblotted with antibodies specific for p21, p27 and actin, respectively.
p21-dependent upregulation of p27 following DNA damage
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sDAP induces preferential increase of p27 in the CDK2
complex
To examine the role of upregulated p27 in DAP-mediated
inhibition of G1-phase CDK, we used CDK4 or CDK2 antibodies
to immunoprecipitate CDK complexes from crude lysates of cells
collected over a 36-h treatment period with DAP, and then
determined the levels of both p21 and p27 in the two G1-phase
CDK complexes. As shown in Figure 4A and B, the level of p21 in
both CDK4 and CDK2 complexes increased from 6 to 24h, which
correlated with the increase in the amount of p21 in crude cell
lysates (see Figure 1B). In contrast, the level of p27 increased
progressively only in the CDK2 complex from 24 to 36h, which
coincided with the increase in p27 in crude cell lysates (cf. Figure
4B and 1B). Increases in cyclin D and E paralleled those of p21 and
p27, and may reflect the role of these inhibitors in the assembly of
CDK complexes.
The results above appear to indicate that DAP treatment
selectively increases p27 within the CDK2 complex, but not
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Figure 3 DAP upregulates the expression of p27 in a p21-dependent
manner. (A) A2780 cells were transfected with control or p21 siRNA for
5h, and then incubated with normal media for 1h before being exposed to
0.6mM DAP or vehicle for another 30h. Cell lysates were then prepared
and analysed by immunoblotting with antibodies specific for p21, p27, p53
and actin. (B) A2780 cells were transfected with 2.5mg of control or myc-
p21 plasmid for 5h. After 24h, lysates of transfected cells were prepared
and immunoblotted with anti-p21, anti-p27 and anti-actin antibodies.
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Figure 4 DAP promotes the preferential increase of p27 in CDK2 complex. (A) Crude lysates of A2780 cells treated with 0.6mM DAP for the indicated
lengths of time were immunoprecipitated with anti-CDK4 antibody, and the immunocomplex was either immunoblotted with anti-CDK4, anti-cyclin D, anti-
p27 or anti-p21 monoclonal antibody (upper panel). The signals from the CDK4, cyclin D, p27 and p21 proteins were quantified by densitometry after
immunoblotting. The ratio of cyclin D, p27 or p21 to CDK4 was calculated, normalised against the level at time 0 and plotted against time (lower panel). (B)
Crude cell lysates of A2780 cells treated with 0.6mM DAP for the indicated lengths of time were immunoprecipitated with anti-CDK2 antibody, and the
immunocomplex was either immunoblotted with anti-CDK2, anti-cyclin E, anti-p27 or anti-p21 monoclonal antibody (upper panel). The signals from the
CDK2, cyclin E, p27 and p21 proteins were quantified after immunoblotting. The ratio of cyclin E, p27 or p21 to CDK2 was calculated, normalised against the
level at time 0 and plotted against time (lower panel). (C) Majority of p27-, CDK2- or CDK4-containing complexes was immunoprecipitated from crude
lysates of control A2780 cells with excess anti-p27, CDK2 or CDK4 antibody, respectively. Immunocomplexes or supernatants after immunoprecipitation
were immunoblotted with anti-p27, anti-CDK2 and anti-CDK4 antibodies. Rabbit IgG was utilised as a control for these antibodies in the experiment. (D)
A2780 cells were transfected with 2.5mg of control or myc-p27 plasmid for 5h. After 24h, lysates of transfected cells were prepared. Majority of cyclin D- or
cyclin E-containing complexes was immunoprecipitated with anti-cyclin D or cyclin E antibody and immunoblotted with anti-myc antibody.
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sCDK4 complex. However, based on literature reports, the CDK4
complex, rather than the CDK2 complex, is the preferential
binding partner of p27 in normal cell lines (Toyoshima and
Hunter, 1994; Poon et al, 1995). In order to determine whether this
was also the case in the A2780 cancer cell line, p27 was
immunoblotted in total CDK4 and CDK2 complexes isolated by
immunoprecipitation from untreated cells. The results in
Figure 4C indicate that immunoprecipitation with the p27 or
CDK4 antibody co-immunoprecipitated all or most of this
inhibitor as assessed by concomitant depletion in the supernatant,
whereas the CDK2 antibody co-immunoprecipitated only
negligible amounts of p27. These findings indicate that untreated
A2780 cells also have most of the p27 bound to CDK4, but not
CDK2. On the other hand, not all of the CDK4 complex was
associated with p27 as immunoprecipitation of p27 in the
supernatant only partially co-immunoprecipitated CDK4. Simi-
larly, most of the CDK4 and CDK2 complex was free of p21 (data
not shown).
To further examine the specificity of p27 binding, we transfected
A2780 cells with different amounts of myc-p27 expression
vector and investigated the distribution of ectopically expressed
p27 between the two CDKs. As shown in Figure 4D, myc-p27
was evenly distributed between total cyclin D (representing
the CDK4 complex) and cyclin E (representing the CDK2
complex) immunoprecipitates when myc-p27 expression was
high, whereas distribution favoured CDK4/cyclin D complex at
lower expressions. The results indicate that in control tumour
cells, both endogenous and exogenous p27 are associated with
the CDK4 complex to a greater extent. In contrast, DAP treatment
promotes the specific increase of p27 in the CDK2 complex
even though substantial levels of CDK4 are available for potential
binding to this inhibitor. It is possible that interaction of p27 with
another protein could alter its preference from CDK4 to CDK2. In
this regard, reports have suggested that cellular increase in p27
may lead to its increased interaction with the modulator protein
Spy1 and, thereby increase incorporation of p27 and Spy1 into the
CDK2 complex (Porter et al, 2003).
DAP treatment does not recruit additional component(s)
into CDK complexes
To explore the possibility that DAP-mediated increase in p27
recruitment within the CDK2 complex, rather CDK4 complex, was
due to binding of a modulator protein, we measured the apparent
molecular size of p27-containing complexes from untreated and
DAP-treated cells by gel filtration and determined whether
p27-containing complexes underwent a size shift in response to
DAP treatment. Calibration of the column with molecular weight
standards showed that this column had a linear separation range of
17–440kDa (data not shown). Western blot analysis of p27 in
eluted fractions no. 19–35 showed that p27 complexes from both
control and DAP-treated cell lysates peaked in fractions 26 and 27,
between the 158- and 44-kDa gel filtration standards, suggesting
that no additional component(s) is associated with p27 complexes
after DAP treatment (Figure 5A and B). To confirm this, we
performed large-scale immunoprecipitation with p27 antibodies
from untreated cells or cells treated with DAP for 30h. The
precipitated proteins were then resolved by SDS–PAGE, visualised
by silver staining, and unique bands following DAP treatment
identified by mass spectrometry. Figure 5C shows result from a
representative p27 immunoprecipitation experiment. Compared to
the control IgG immunoprecipitate (lane a), the p27 immunopre-
cipitate from control cell lysate contained five major bands and
several minor bands (lane b). These bands were also present at
almost similar intensities in the p27 immunoprecipitate from DAP-
treated cell lysate (lane c). Interestingly, the p27 antibody
precipitated only two unique bands from DAP-treated cell lysate;
one migrated at about 50kDa and the other at about 32kDa (lane c).
By mass spectrometry, they were identified as cyclin E and CDK2,
respectively, confirming our observations that DAP treatment
effectively increases the amount of p27 in the CDK2/cyclin E
complex (see Figure 4B). Taken together, the data from gel filtration
chromatography and large-scale immunoprecipitation of p27 did
not reveal any additional components that may explain increased
binding of p27 to the CDK2 complex after DAP treatment.
Upregulated p27 inhibits CDK2 kinase activities
As Figure 3 demonstrated that DAP-induced p21 is responsible for
the increase in the total level of p27, it was necessary to examine
whether p21 was also required for increasing p27 in the CDK2
complex following DAP treatment, and if this resulted in p27-
dependent inhibition of CDK2 kinase activity. To explore this
possibility, we prevented DAP-mediated induction of p21 by
siRNA and determined the effect on p27 levels in CDK4 and CDK2
complexes. Immunoblots of p27 in CDK4 immunoprecipitates
showed that p21 siRNA did not affect the level of p27 in CDK4
complex following DAP treatment (Figure 6A). In contrast, the
high level of p27 in CDK2 complex in DAP-treated cells was
substantially suppressed by knockdown of p21 expression,
indicating that the increase of p27 in CDK2 complex is dependent
on p21. However, whether the induced p21 regulated p27 levels in
CDK2 by direct binding or through an indirect mechanism needed
to be resolved. Therefore, we performed reciprocal immuno-
precipitation with p21 or p27 antibody and examined whether p21
and p27 co-existed within the immunoprecipiate from control or
DAP-treated cells. As shown in Figure 6B, p21 and p27 did not
physically interact, and, therefore, did not co-exist within the same
CDK complex in untreated or DAP-treated cell lysate. This
excluded the possibility that p21 regulates p27 through direct
binding.
Although our data show that DAP-induced p21 is responsible
for increasing p27 in CDK2 complex, the functional consequence
of this required examination. Therefore, we immunoprecipitated
majority of p21- or p27-bound CDK2 complexes with excessive
levels of p21 or p27 antibodies and then measured the
relative amounts of CDK2 complex to which they were bound in
cells exposed to DAP. As expected from Figure 6B, immuno-
precipitation of p21 or p27 from DAP-treated cell lysates
substantially depleted the inhibitor from the cell lysate, but
did not co-deplete the second inhibitor (Figure 6C). Immunoblots
and densitometry of cyclin E in immunoprecipitates indicated
that the level of CDK2/cyclin E complex associated with p21 was
about three times higher than with p27 (Figure 6C). Previously,
we have reported that most of the CDK2 complexes contained p21
and p27 after DAP treatment (He et al, 2005), but in the present
study, we demonstrate that p21 and p27 do not co-exist. Taken
together, the results in Figure 6C indicate that p21 is bound to
about 75% CDK2/cyclin E complex and p27 to the remaining 25%.
We have previously demonstrated that this p21 binding drama-
tically decreases CDK4 or CDK2 activities of the CDK4 or CDK2
immunoprecipitate after p27 was immunodepleted (He et al, 2005).
Therefore, in the present study, it was of interest to examine if p27-
containing CDK2 complex was also inactive. For this purpose, we
immunoprecipitated, using either CDK2 (Figure 6D, left panel) or
cyclin E (right panel) antibodies, CDK2 complexes from p21- and
p27-depleted control cell lysates or p27-associated CDK2 complex
from p21-depleted DAP cell lysates. As shown in Figure 6D, CDK2/
cyclin E complex lacking p27 was active (left lane), whereas that
associated with p27 was inactive (right lane). This demonstrates
that p27 effectively inhibits the kinase activity of the CDK2/cyclin
E complex.
In summary, these results demonstrate that p27 levels in the
CDK2 complex is regulated by DAP-induced p21, and stabilisation
of p27 within the complex inhibits CDK2 activity.
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sDISCUSSION
Our present study demonstrates that p21 not only inhibits CDK
activity directly, but also indirectly through stabilising p27 protein
that increases cellular levels of this inhibitor. Moreover, DAP-
induced p21 promotes the selective increase of p27 in CDK2
complexes, and not in CDK4 complexes, and this selective increase
contributes to the inhibition of CDK2 kinase activity. Thus, our data
provide evidence that p27 contributes to DAP-induced G1-phase
checkpoint response in a manner similar to that observed with p21.
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Figure 5 DAP treatment does not recruit new component(s) into p27-containing complexes. (A) Crude cell lysates prepared from untreated cells were
fractionated on a 40-ml gel filtration AcA34 column. Proteins from fractions 19–35 were separated by SDS–PAGE, electrophoretically blotted onto
nitrocellulose membranes, and immunoblotted with anti-p27 antibody. (B) Crude cell lysates made from DAP-treated (0.6mM; 24h) cells were fractionated
by gel filtration and immunoblotted with anti-p27 antibody, as described above in (A). (C) Large-scale immunoprecipitation of untreated or DAP-treated
(0.6mM; 24h) A2780 cell lysates was performed with covalently linked anti-p27 or control rabbit IgG; eluted polypeptides from antibody beads were then
resolved by SDS–PAGE and visualised by silver staining. CDK2 and cyclin E immunoprecipitated by anti-p27 antibody following DAP treatment were
identified by mass spectrometry. Lane a: Rabbit IgG immunoprecipitates of untreated cell lysates. Lane b: Anti-p27 immunoprecipitates of untreated cell
lysates. Lane c: Anti-p27 immunoprecipitates of DAP-treated cell lysates.
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sThis is the first evidence that p27 regulation is linked directly to
activation of the p53/p21 pathway by a DNA-damaging agent.
Hyperproliferation of cancer cells is associated with deregula-
tion of cell cycle progression, which is driven by the activities of
CDKs. Therefore, inhibition of CDK activity is a realistic goal in
the clinical management of cancer (McDonald III and El Deiry,
2000; Malumbres and Carnero, 2003). This is particularly evident
from studies with selective small molecule CDK inhibitors, which
halt G1/S transition and induce cell death (Senderowicz, 2003). The
vital contribution of DAP-induced p27 in inhibiting CDK2 in much
the same way likely contributes to the cellular effects of this novel
platinum agent. This is consistent with the acknowledged
significance of p27 in cancer progression and antitumour drug
response, and stems from the reported correlation between low
p27 expression and either high tumour grades or poor survival
following chemotherapy treatment (Sgambato et al, 2000; Nho and
Sheaff, 2003). Conversely, its overexpression in cancer cells
inhibits tumour cell growth by enforcing cell cycle arrest and
apoptosis, and this has contributed to p27 being referred to as a
tumour suppressor (Katayose et al, 1997; Wang et al, 1997).
Likewise, p21 is also now becoming recognised as a tumour
suppressor (Brugarolas et al, 1998; Martin-Caballero et al, 2001),
and this is in concordance with its role in facilitating cisplatin-
induced cell death when overexpressed ectopically (Lincet et al,
2000; Qin and Ng, 2001, 2002). In consonant with this, deletion
or depletion of p21 inhibits apoptosis and induces resistance
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Figure 6 Induction of p21 by DAP stabilises p27 protein in CDK2 complex to inhibit its kinase activity. (A) As described in Figure 3A, lysates were
prepared from cells exposed to p21 siRNA and 0.6mM DAP, and then immunoprecipitated with anti-CDK4 or CDK2 antibody. The immunoprecipitates
were separated by SDS–PAGE and immunoblotted with antibody specific to p21, p27, CDK4, CDK2, cyclin D1 or cyclin E. (B) Crude cell lysates made
from control or DAP-treated (0.6mM; 30h) A2780 cells were immunoprecipitated with either anti-p21 or anti-p27 antibodies, and the precipitated proteins
were immunoblotted with anti-p21 or anti-p27 antibody. (C) Majority of p21- or p27-containing complexes was immunoprecipitated from DAP-treated
(0.6mM; 30h) A2780 cell lysates with excess anti-p21 or anti-p27 antibody. The immunoprecipitate (IP) was separated by SDS–PAGE and immunoblotted
with anti-cyclin E antibody. Supernatants (SN) were immunoblotted with anti-p21 or anti-p27 antibody to ensure respective immunoprecipitation was
quantitative. (D) CDK2 complexes were immunoprecipitated with anti-CDK2 (left panel) or anti-cyclin E (right panel) antibodies from either control A2780
cell lysate, which had been depleted of p21 and p27-containing complexes with respective antibodies (left lane), or DAP-treated (0.6mM; 30h) cell lysate, in
which only the p21-containing complexes had been immunodepleted (right lane). CDK2, cyclin E, p27 and p21 in these immunoprecipitates were subjected
to immunoblot analysis, and CDK2 activities were determined as described in Experimental Procedures.
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s(Hsu et al, 1999), which is in agreement with the reported failure of
cisplatin to upregulate p21 in cisplatin-resistant tumour cells
(Mujoo et al, 2003, 2005). In contrast, several reports have
provided evidence that p21 protects cells from apoptosis (Gartel
and Tyner, 2002; Liu et al, 2003), and this makes it likely that cell
context and the cellular signalling pathway induced by the specific
chemotherapeutic drug determine whether p21 facilitates or
antagonises apoptosis. With DAP, however, expression of p21 is
crucial for CDK inhibition and to prevent cell proliferation (Kuang
et al, 2001; He et al, 2005), and it is likely from the present studies
that these effects are mediated in part through p21-dependent
stabilisation of p27 within the CDK2 complex.
Regulation of p27 in human cancers is predominantly through a
mechanism involving Skp2-mediated proteosomal degradation of
p27 (Bloom and Pagano, 2003). Furthermore, CDK2/cyclin E-
dependent phosphorylation of p27 at Thr-187 has been suggested
as essential for the recognition of p27 by Skp2. Therefore,
downregulation of Skp2 level or inhibition of proteasomal activity,
as in this study with MG132, increases p27 level. As we have
demonstrated that increases in p27 by DAP are dependent on p21,
the observed p21-mediated inhibition of CDK2 activity is the likely
mechanism, with resultant decrease in phosphorylation of p27.
Although previous reports have suggested that p27 upregulation
may involve p21 (Liu et al, 2000; Steinman et al, 2001; Munoz-
Alonso et al, 2005), the present study not only provides definitive
evidence for this, but also demonstrates for the first time that this
upregulation is robust, inhibits CDK2/cyclin E and occurs in
response to DNA damage.
Unlike previous reports on the induction of p27 by ionising
radiation or antitumour agents (Vikhanskaya et al, 1996;
Balasubramanian et al, 1999; Vivo et al, 2003; Zhou et al, 2004),
we have examined not only the overall upregulation of p27 by
DAP, but also its increase specifically within the CDK2 complex to
better understand the contribution to CDK2 inhibition. Our data
provide direct evidence that p27 is responsible for B25% of the
inhibited CDK2, with the remaining inhibition attributable to p21.
The relatively lower contribution of p27 is surprising, considering
that the absolute amount of p27 in the cell after DAP treatment is
similar to or greater than that of p21. This inconsistency may be
explained by the possibility that either the stoichiometry of
p27:CDK2 is greater than that for p21:CDK2 in the inhibited
complex, or that a portion of the induced p27 has functions other
than in CDK inhibition. Although it is not clear from these studies
whether there is sufficient induction of p21 to inhibit all CDK2
molecules if p27 were absent, it is overtly apparent that DAP-
induced p27, like p21, contributes significantly to the inhibition of
CDK2 activity. On the other hand, as p27 levels are not altered in
the CDK4 complex, and p27 and p21 do not co-exist within the
same complex, it is likely that p27-free CDK4 complexes are
inhibited predominantly through recruitment of DAP-induced p21.
Our study has also brought awareness to the novel observation
that p21-dependent increases of p27 are only reflected within the
CDK2 complex, and not CDK4 complex. With the data available, it
is possible to propose a conceptual model to explain the induction
of p27 by DAP. In this model, basal levels of p27, which are
regulated independently of p21, are recruited into both CDK4 and
CDK2 complexes (Figure 7). However, the recruitment of p27 into
the CDK2 complex results in immediate phosphorylation of the
inhibitor by CDK2 activity that leads to rapid degradation of p27
via the ubiquitin pathway. Based on literature evidence, the p27
bound to CDK2 does not undergo intramolecular phosphorylation,
but it is phosphorylated by the active CDK2 complex that is free of
p27 (Montagnoli et al, 1999; Xu et al, 1999). Consequently, the p27
associated with CDK2 is kept to a relatively low level. Once p21 is
induced, it inhibits CDK2 and, thereby prevents p27 phosphoryla-
tion; this stabilises and increases the level of p27 within the CDK2
complex, which then becomes inhibited. Based on such a model,
CDK2 inhibition will need to reach a critical threshold level before
p27 within the CDK2 complex is stabilised, and this may well
explain the observed three-fold greater contribution to CDK2
inhibition of p21 than p27. In contrast, the p27 associated with
CDK4 is not susceptible to phosphorylation by CDK2, and so the
inhibitor remains in a stabilised form within the CDK4 complex
(Sheaff et al, 1997; Vlach et al, 1997). This is supported by our
results with p21-siRNA, which maintains CDK2 in an active state
but does not reduce to any degree the level of p27 bound to the
CDK4 complex.
In conclusion, our data highlight the significance of p21 and p27
expression in DAP-mediated G1-phase cell cycle arrest in order to
prevent G1/S transition. More importantly, we have provided
evidence that increased association of p27 within the CDK2
complex is mediated through a p21-dependent pathway, which
prevents destabilising phosphorylation of p27. We have previously
demonstrated the importance of the p53/p21 pathway in cell cycle
effects of DAP. Based on our present study, which demonstrates
substantial p27 induction and p27-dependent inhibition of CDK2
by DAP, it is appropriate for the p53/p21/p27 axis to assume
greater prominence and become a new focus of attention in
checkpoint response to DNA damage.
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